BPC-157 vs TB-500: The Healing Peptide Comparison (2026)

BPC-157, "Body Protection Compound-157," is a synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of human gastric juice protein^[1]. Unlike most therapeutic peptides, its sequence shares no homology with any known endogenous human peptide, which is part of why it's been so difficult to characterize pharmacokinetically^[1].

What it does mechanistically: BPC-157 upregulates growth factor expression, particularly VEGF (vascular endothelial growth factor) and EGR-1 (early growth response-1), at the site of injury^[1][2]. It stimulates fibroblast proliferation, increases nitric oxide production, and drives angiogenesis. The effect is predominantly localized rather than systemic.

Clinical status: This is the uncomfortable part. When I went through the human trial literature, there are only three published pilot studies on injectable BPC-157 as of early 2026^[4][5]. The original Phase I safety trial (NCT02637284) enrolled 42 healthy volunteers in 2015 but was cancelled and never published results. No public explanation was given^[4][5]. A 2025 IV safety pilot (PMID 40131143) administered 10 mg and 20 mg doses to two adults with no measurable adverse effects on cardiac, liver, kidney, or thyroid biomarkers^[5]. That's the extent of the rigorous human data. Everything else on BPC-157 is preclinical (rodent models) or retrospective clinical observation^[4].

Regulatory: The FDA placed BPC-157 on its Category 2 bulk drug substance list in 2023, effectively blocking compounding pharmacies from preparing it^[1]. On February 27, 2026, HHS Secretary RFK Jr. announced that approximately 14 of the 19 restricted peptides, including BPC-157, are expected to move back to Category 1, though as of this writing the FDA hasn't formally published the revised list^[10]. Follow PepPal's news coverage of the Category 2 reclassification for updates.

For a full dosing protocol with titration, reconstitution tables, and clinical references, see the BPC-157 protocol page on PDP.

TB-500 is a synthetic analog of thymosin beta-4 (Tβ4), a 43-amino-acid peptide naturally present in almost every cell in the human body^[6][7]. The "TB-500" product is N-terminally acetylated, which protects it from serial cleavage at the C-terminus by human liver microsomes, essentially making it more stable than native Tβ4 would be^[7]. Functionally, TB-500 and thymosin beta-4 are treated as equivalent in the literature.

What it does mechanistically: TB-500's primary target is actin, the most abundant structural protein in mammalian cells^[6]. By binding and sequestering G-actin (monomeric actin), TB-500 regulates the rate at which cells can form filaments, change shape, and migrate. When tissue is injured, cells need to move to the injury site, divide, and rebuild; TB-500 accelerates that migration step^[6][7]. Secondary effects include angiogenesis via cell-surface ATP synthase interaction, and anti-inflammatory signaling.

Clinical status: TB-500 has more actual human data than BPC-157, though still nowhere near FDA approval. RegeneRx Biopharmaceuticals ran Phase II trials in venous stasis ulcers (NCT00832091) and neurotrophic keratopathy (dry eye) through the 2010s^[6][8]. A Phase I IV safety trial with synthetic Tβ4 at doses from 42 mg to 1260 mg over 14 days reported no dose-limiting toxicities and a dose-proportional pharmacokinetic profile^[9]. The venous ulcer trial showed a 45% improvement in median wound healing time vs. placebo in fully healed patients^[6][8]. RegeneRx ultimately couldn't fund Phase III, which is a pattern with peptides that can't be strongly patented.

Regulatory: TB-500 is on the FDA Category 2 list alongside BPC-157 and subject to the same February 2026 reclassification signal^[10]. It's banned by WADA under class S0 (Non-Approved Substances) and is detectable in anti-doping screens^[8].

For dosing and reconstitution specifics, see the TB-500 protocol page on PDP.

Think of tissue repair like rebuilding a damaged section of a city. You need two things: a loud signal at the damaged street corner telling construction crews and supply trucks to show up, and a highway system that can move crews from anywhere in the city to that corner. BPC-157 is the loud signal. TB-500 is the highway.

BPC-157's signal model. The pentadecapeptide binds near the injury site and upregulates VEGF, which drives new blood vessel formation into the damaged tissue^[1][2]. Simultaneously it stimulates fibroblast migration and collagen deposition, and increases local nitric oxide, which modulates vascular tone and inflammation. The outcome is measurable improvement in tendon-to-bone healing, intestinal anastomosis strength, and ligament repair in rodent models, though, as I noted, human data is very thin.

TB-500's mobilization model. Tβ4 doesn't just signal. It actively regulates the cellular machinery that lets cells move^[6][7]. By sequestering G-actin monomers, TB-500 controls how quickly cells can rebuild their cytoskeleton and migrate. When wound fluid is analyzed, Tβ4 is one of the most abundant proteins present. Your body is already deploying it naturally at injury sites^[7]. Administering synthetic TB-500 amplifies that mobilization systemically.

The mechanistic non-overlap is why the two peptides aren't redundant. You can upregulate VEGF with BPC-157 all day, but if the cells that need to migrate to the injury don't mobilize fast enough, you don't get the same outcome you'd get from running both.

This is the decision most researchers actually need to make. Here's how I'd frame it based on the mechanistic data and the published use cases.

Choose BPC-157 when the research target is local. Tendinopathy, ligament strain, specific joint pain, gut-related inflammation, or a well-localized musculoskeletal injury. The pentadecapeptide's strength is delivering a strong local healing signal, especially when injected near the affected tissue^[1][2]. It's also the only one of the two with any evidence of oral bioavailability for gut-targeted effects^[4].

Choose TB-500 when the research target is systemic. Post-surgical recovery across multiple tissue types, cardiovascular tissue, broad inflammatory conditions, or when an injury is too diffuse to localize (e.g., chronic overuse syndromes). TB-500's systemic cell-migration effect is exactly what broad-spectrum recovery scenarios call for^[6][7].

Choose both (the Wolverine Stack) when the goal is comprehensive recovery. This is the most common use pattern in the research community. BPC-157 delivers the localized fibroblast and angiogenic signal; TB-500 mobilizes the systemic cell migration response. For a full stacked protocol with loading/maintenance schedules and reconstitution math, see How Do You Get the Wolverine Stack or the Wolverine Stack protocol page. Also read Peptide Stacking 101 for general stack-design principles before combining.

These are community-derived protocols, not clinical-trial titration schedules. No randomized human trial has established optimal dosing for either peptide at the doses currently used in research settings^[4][6]. Dosing data below is extrapolated from preclinical studies, retrospective clinical observation, and community protocols, always labeled as community-derived.

When I ran the math for a typical 8-week Wolverine Stack cycle at 500 mcg BPC-157 daily + 5 mg TB-500 loading (2× weekly for 4 weeks) then 2 mg maintenance, the total compound required is roughly 28 mg BPC-157 and 28 mg TB-500. That works out to one 10 mg BPC-157 vial per month and one 10 mg TB-500 vial covering ~4–5 weeks.

For a full loading/maintenance titration schedule with weekly dosing grids, see the individual BPC-157 protocol and TB-500 protocol pages on PDP.

Reconstituting these two peptides uses the same procedure (see How to Reconstitute Peptides for the step-by-step), but the math differs because of the very different dose scales: BPC-157 is dosed in micrograms; TB-500 is dosed in milligrams. I ran these tables at 2 mL BAC water, which is the most common reconstitution volume for both compounds.

Unit reminder: BPC-157 is dosed in micrograms (mcg). TB-500 is dosed in milligrams (mg). A 500 mcg BPC-157 dose is 0.5 mg, ten times smaller than a typical TB-500 dose. Confusing the two is one of the most common mistakes with this stack, and the consequences range from sub-therapeutic dosing (too little) to wasted product (too much). Label both vials clearly and never share a syringe between them.

For custom vial sizes, water volumes, or dose levels not shown above, use the free PepPal Reconstitution Calculator; it handles the unit conversion between mcg and mg automatically.

Both peptides have favorable safety profiles in the human data that exists, but the data that exists is limited.

BPC-157 side effects. The 2025 IV safety pilot reported no measurable effects on cardiac, liver, kidney, thyroid, or blood glucose biomarkers at 10 mg and 20 mg IV doses, but that's a two-person sample^[5]. The 2016 orthopedic systematic review noted that anonymous online users report injection site pain, joint pain, anxiety, heart palpitations, fatigue, and mood changes, but these are self-reported and uncontrolled^[1]. Given the absence of rigorous pharmacokinetic data and the 12–58% contamination rate documented across ergo-nutritional supplements^[1], product quality matters more than dose precision here. Red flags for BPC-157 specifically are dose-dependent fatigue in the first week and any cardiovascular symptom.

TB-500 side effects. The Ruff 2010 Phase I trial administered IV doses up to 1260 mg for 14 days with no dose-limiting toxicities and only mild-to-moderate treatment-emergent adverse events^[9]. Subcutaneous dosing at 2–5 mg/week produces a substantially lower plasma exposure than the Phase I IV doses. The main theoretical concern flagged in the literature is enhanced angiogenesis in the context of undiagnosed malignancy, which is why I published a separate guide on TB-500 and cancer risk that covers the Tβ4-overexpression data vs. exogenous TB-500 findings in detail.

Both compounds: Injection-site reactions (redness, temporary soreness) are the most common community-reported effect. Contamination from unverified suppliers is a much larger practical risk than direct peptide toxicity, which is why supplier vetting matters more than most discussions of these peptides acknowledge.

Both peptides are widely available through grey-market research peptide suppliers. Availability isn't the problem. Purity verification is.

Based on the Finnrick Analytics test reports I've reviewed, two suppliers consistently deliver A-grade quality for both compounds:

• Peptide Partners: Finnrick A rating across 59 tested samples in multiple product categories including BPC-157 and TB-500. USA-based, same-day FedEx 2-Day shipping, multi-lab verification. This is PepPal's #1 pick for most buyers and the supplier I personally reference most often in the Wolverine Stack context. Affiliate link: use code PEPPAL at checkout.
• Orbitrex Peptides: Finnrick A-rated with a broader catalog and single-vial order support, which makes them a stronger fit if you only need one compound at a time rather than a full stack. Affiliate link: use code PEPPAL at checkout.

For the full side-by-side supplier breakdown, see Peptide Partners vs Orbitrex Peptides. For the broader grey-market landscape including alternatives, see Best Grey Market Peptide Suppliers (2026). And regardless of which supplier you use, verify every order with a third-party COA. How to Read a Peptide COA covers what to look for on the test report.

Running both peptides is mechanically simple, but there are a handful of recurring mistakes I see in forum threads and supplier support tickets:

• Mixing BPC-157 and TB-500 in a single vial. Don't. Both compounds are more stable reconstituted separately, and combining them introduces compatibility unknowns that aren't supported by any stability data I've seen. Use separate vials and separate syringes.
• Confusing mcg and mg dosing. BPC-157 at 500 mcg and TB-500 at 5 mg look similar on a syringe if you've just reconstituted both at the same concentration, but 500 mcg = 0.5 mg, which is 10× smaller than a typical TB-500 dose. Label every vial.
• Dosing TB-500 daily. TB-500's longer half-life^[9] makes daily dosing unnecessary. Twice-weekly loading followed by once-weekly maintenance is the standard community protocol. Daily dosing burns through product without improving the outcome.
• Ignoring supplier verification. The single biggest variable in whether these peptides work is whether you're actually getting what's on the label. Without a third-party COA, you're trusting the vendor's QC blindly.
• Running too long. Both compounds are typically cycled 4–8 weeks on, 2–4 weeks off. Continuous year-round dosing isn't supported by any data and isn't how these compounds appear in the available clinical protocols.

• Calculate your dosing: PepPal Reconstitution Calculator handles BPC-157 (mcg) and TB-500 (mg) math automatically.
• Buy from verified suppliers: Peptide Partners (#1 pick) or Orbitrex Peptides (single-vial orders). Use code PEPPAL.
• Run the full stack: How Do You Get the Wolverine Stack and the Wolverine Stack protocol on PDP.
• Deep-dive each compound: BPC-157 protocol · TB-500 protocol.
• Learn the prep workflow: How to Reconstitute Peptides · How to Read a Peptide COA.